CN102186842B - 异羟肟酸衍生物 - Google Patents

异羟肟酸衍生物 Download PDF

Info

Publication number
CN102186842B
CN102186842B CN201080002890.XA CN201080002890A CN102186842B CN 102186842 B CN102186842 B CN 102186842B CN 201080002890 A CN201080002890 A CN 201080002890A CN 102186842 B CN102186842 B CN 102186842B
Authority
CN
China
Prior art keywords
cancer
compound
compounds
mmol
add
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080002890.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN102186842A (zh
Inventor
陈愉
陈怡�
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Stno Medical Science And Technology Co Ltd
Original Assignee
Hangzhou Minsheng Pharmaceutical Co Ltd
Northlake Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Minsheng Pharmaceutical Co Ltd, Northlake Biosciences LLC filed Critical Hangzhou Minsheng Pharmaceutical Co Ltd
Publication of CN102186842A publication Critical patent/CN102186842A/zh
Application granted granted Critical
Publication of CN102186842B publication Critical patent/CN102186842B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0013—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
CN201080002890.XA 2009-01-23 2010-01-07 异羟肟酸衍生物 Active CN102186842B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US14700209P 2009-01-23 2009-01-23
US61/147,002 2009-01-23
US15649609P 2009-02-28 2009-02-28
US61/156,496 2009-02-28
US25215609P 2009-10-15 2009-10-15
US61/252,156 2009-10-15
US25265209P 2009-10-17 2009-10-17
US61/252,652 2009-10-17
PCT/US2010/020373 WO2010085377A2 (en) 2009-01-23 2010-01-07 Hydroxamic acid derivatives

Publications (2)

Publication Number Publication Date
CN102186842A CN102186842A (zh) 2011-09-14
CN102186842B true CN102186842B (zh) 2014-07-23

Family

ID=42356377

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080002890.XA Active CN102186842B (zh) 2009-01-23 2010-01-07 异羟肟酸衍生物

Country Status (17)

Country Link
US (3) US8609864B2 (enExample)
EP (1) EP2389375B1 (enExample)
JP (1) JP5576402B2 (enExample)
CN (1) CN102186842B (enExample)
CA (1) CA2750413C (enExample)
CY (1) CY1116602T1 (enExample)
DK (1) DK2389375T3 (enExample)
ES (1) ES2544803T3 (enExample)
HR (1) HRP20150778T1 (enExample)
HU (1) HUE025349T2 (enExample)
ME (1) ME02254B (enExample)
PL (1) PL2389375T3 (enExample)
PT (1) PT2389375E (enExample)
RS (1) RS54192B1 (enExample)
SI (1) SI2389375T1 (enExample)
SM (1) SMT201500196B (enExample)
WO (1) WO2010085377A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2562175A1 (en) 2008-01-22 2013-02-27 Dow AgroSciences LLC 5-fluoro pyrimidine derivatives as fungicides
RS54192B1 (sr) * 2009-01-23 2015-12-31 Euro-Celtique S.A. Derivati hidroksamske kiseline
UA112284C2 (uk) 2009-08-07 2016-08-25 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Похідні 5-фторпіримідинону
JP5784603B2 (ja) 2009-08-07 2015-09-24 ダウ アグロサイエンシィズ エルエルシー Ｎ１−スルホニル−５−フルオロピリミジノン誘導体
UA107671C2 (en) * 2009-08-07 2015-02-10 Dow Agrosciences Llc N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
UA106889C2 (uk) 2009-08-07 2014-10-27 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Похідні n1-ацил-5-фторпіримідинону
CA2786250A1 (en) 2010-01-07 2011-07-14 Dow Agrosciences Llc Thiazolo[5,4-d] pyrimidines and their use as agrochemicals
CN101928234B (zh) * 2010-01-15 2012-12-12 北京欧凯纳斯科技有限公司 6/7-（杂）芳基-n-羟基己/庚酰胺化合物及其制备方法
WO2011113175A1 (zh) * 2010-03-15 2011-09-22 Gao Feng 阿糖胞苷前药衍生物及其在抗癌抗肿瘤中的用途
CN103313992B (zh) * 2011-01-12 2016-04-27 天堃医药科技（杭州）有限公司 具有hdac抑制作用的喜树碱衍生物
ES2646725T3 (es) 2011-08-17 2017-12-15 Adama Makhteshim Ltd. Derivados 1-sustituidos de 5-fluoro-3,6-dihidro-6-imino-2(1H)-pirimidinona como agentes fungicidas para uso en protección de plantas
CN102993102B (zh) * 2011-09-16 2016-08-24 杭州民生药业有限公司 [1-甲基-2-(7’-庚异羟肟酸基)-5-n，n-二(2’-氯乙基)]-1h-苯并咪唑的合成方法
MX346432B (es) * 2011-09-18 2017-03-21 Euro-Celtique S A * Composiciones farmaceuticas.
CN102432654A (zh) * 2011-09-26 2012-05-02 宋云龙 吉西他滨酰胺衍生物及其制备方法和用途
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
CN102584737A (zh) * 2012-02-07 2012-07-18 盛世泰科生物医药技术(苏州)有限公司 抑制组蛋白去乙酰酶的物质的组成和使用
EP2725029A1 (en) * 2012-10-29 2014-04-30 Laboratoire Biodim New antibacterial compounds and biological applications thereof
EP2945635A4 (en) 2012-12-28 2016-05-25 Dow Agrosciences Llc 1- (SUBSTITUTED BENZOYL) -5-FLUORO-4-IMINO-3-METHYL-3,4-DIHYDROPYRIMIDIN-2 (1H) -ONE DERIVATIVES
KR20150103096A (ko) 2012-12-28 2015-09-09 다우 아그로사이언시즈 엘엘씨 N-(치환된)-5-플루오로-4-이미노-3-메틸-2-옥소-3,4-디히드로피리미딘-1(2h)-카르복실레이트 유도체
MX2015008444A (es) 2012-12-28 2015-09-23 Dow Agrosciences Llc Derivados de n-(sustituido)-5-flouro-4-imino-3-metil-2-oxo-3,4-dih idropirimidin-1 (2h)-carboximida.
CA2894553C (en) 2012-12-31 2021-03-02 Dow Agrosciences Llc 3-alkyl-5-fluoro-4-substituted-imino-3,4-dihydropyrimidin-2(1h)-one derivatives as fungicides
CN103340845B (zh) * 2013-06-26 2015-03-18 浙江省食品药品检验研究院 药物组合物
JP6212831B2 (ja) * 2013-12-04 2017-10-18 杭州源昶医薬科技有限公司 ゲムシタビン誘導体、該誘導体を含む組成物及び該誘導体の製薬用途
SG11201605377VA (en) 2013-12-31 2016-08-30 Adama Makhteshim Ltd 5-fluoro-4-imino-3-(alkyl/substituted alkyl)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one and processes for their preparation
EA030056B1 (ru) 2013-12-31 2018-06-29 Адама Мактешим Лтд. Синергетические фунгицидные смеси и синергетические фунгицидные композиции для борьбы с грибами
CA2934902C (en) 2014-02-03 2018-08-14 Halliburton Energy Services, Inc. Geomechanical and geophysical computational model for oil and gas stimulation and production
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) * 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
AU2015338042A1 (en) * 2014-10-28 2017-04-27 Shionogi & Co., Ltd. Heterocyclic derivative having AMPK activating effect
CN108026057B (zh) 2015-05-22 2021-08-06 株式会社钟根堂 用作选择性组蛋白脱乙酰酶抑制剂的杂环烷基衍生化合物及含其的药物组合物
JP2018529681A (ja) * 2015-09-10 2018-10-11 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ シクロホスファミド及びイホスファミドのイムノアッセイ用の免疫原及びアッセイ接合体として用いるシクロホスファミド類似体
US11266631B2 (en) 2016-10-11 2022-03-08 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy
CN106905191B (zh) * 2017-03-05 2019-03-29 北京化工大学 一种含有羟肟酸基团的氮芥类化合物及其制备方法和用途
CN106883217B (zh) * 2017-04-01 2020-05-22 清华大学深圳研究生院 一种核苷碱基异羟肟酸衍生化合物及其制备方法与应用
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709405D0 (en) * 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
EP3659307A4 (en) * 2017-07-28 2021-09-22 Yale University ANTI-CANCER PRODUCTS AND METHOD FOR MANUFACTURING AND USING THEREOF
AU2018337035B2 (en) 2017-09-21 2023-10-12 Becton, Dickinson And Company Demarcation template for hazardous contaminant testing
AU2018337650B2 (en) 2017-09-21 2025-04-24 Becton, Dickinson And Company High dynamic range assays in hazardous contaminant testing
USD859683S1 (en) 2017-09-21 2019-09-10 Becton, Dickinson And Company Collection device
CA3075773A1 (en) 2017-09-21 2019-03-28 Becton, Dickinson And Company Hazardous contaminant collection kit and rapid testing
CN108299313B (zh) * 2018-01-16 2020-10-02 长沙霍滋生物科技有限公司 一种化合物及其在药学上的应用
SG11202100411TA (en) * 2018-08-03 2021-02-25 Cellix Bio Private Ltd Compositions and methods for the treatment of cancer
CN109516957A (zh) * 2018-08-03 2019-03-26 杭州梯诺医药科技有限公司 Nl-101多晶型及其制备方法
EP3845544B1 (en) * 2018-09-01 2023-11-15 Beijing Showby Pharmaceutical Co., Ltd. Phosphate of platinum compound and preparation method therefor
AU2019400983B2 (en) 2018-12-18 2025-07-03 Mundipharma International Corporation Limited Compounds for treating multiple myeloma
JP7479385B2 (ja) 2019-01-28 2024-05-08 ベクトン・ディキンソン・アンド・カンパニー 一体化されたスワブ及び検査デバイスを有する有害汚染物質採取デバイス
CN112209884B (zh) * 2019-07-12 2022-11-11 杭州梯诺医药科技有限公司 1-h苯并咪唑衍生物、制备方法及其应用
CN113307829B (zh) * 2021-05-08 2022-05-24 苏州科技大学 一种以异羟肟酸衍生物为配体的铂(ii)配合物及其制备方法和应用
WO2024231293A1 (en) 2023-05-05 2024-11-14 Euro-Celtique S.A. Combinations for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008050125A1 (en) * 2006-10-24 2008-05-02 Imperial Innovations Ltd. Compounds and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
EP2083005A1 (en) 2000-09-29 2009-07-29 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
US8227636B2 (en) * 2004-04-05 2012-07-24 Merck Hdac Research, Llc Histone deacetylase inhibitor prodrugs
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
WO2009100045A1 (en) * 2008-02-04 2009-08-13 Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
RS54192B1 (sr) * 2009-01-23 2015-12-31 Euro-Celtique S.A. Derivati hidroksamske kiseline

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008050125A1 (en) * 2006-10-24 2008-05-02 Imperial Innovations Ltd. Compounds and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bendamustine in the treatment of chronic lymphocytic leukemia;Wolfgang Knauf;《Expert reviews anticancer therapy》;20090201;第9卷(第2期);165-174 *
Histone Deacetylase Inhibitors: From Bench to Clinic;Marielle Paris，等;《Journal of Medicinal Chemistry》;20080205;第51卷(第6期);1505-1529,Figure 3,4 *
Histone Deacetylase Inhibitors;Thomas A. Miller，等;《Journal of Medicinal Chemistry》;20031028;第46卷(第24期);5097-5116 *

Also Published As

Publication number Publication date
EP2389375A2 (en) 2011-11-30
JP5576402B2 (ja) 2014-08-20
USRE46144E1 (en) 2016-09-13
JP2012515776A (ja) 2012-07-12
CY1116602T1 (el) 2018-03-07
PT2389375E (pt) 2015-09-17
ES2544803T3 (es) 2015-09-04
SI2389375T1 (sl) 2015-11-30
CN102186842A (zh) 2011-09-14
CA2750413C (en) 2016-06-21
US8609864B2 (en) 2013-12-17
WO2010085377A3 (en) 2011-03-31
RS54192B1 (sr) 2015-12-31
WO2010085377A2 (en) 2010-07-29
HUE025349T2 (en) 2016-02-29
US20110269706A1 (en) 2011-11-03
PL2389375T3 (pl) 2015-11-30
HRP20150778T1 (hr) 2015-08-28
US9096627B2 (en) 2015-08-04
DK2389375T3 (en) 2015-08-24
US20140066419A1 (en) 2014-03-06
CA2750413A1 (en) 2010-07-29
EP2389375B1 (en) 2015-05-20
EP2389375A4 (en) 2012-09-19
ME02254B (me) 2015-12-31
SMT201500196B (it) 2015-10-30

Similar Documents

Publication Publication Date Title
CN102186842B (zh) 异羟肟酸衍生物
ES2696526T3 (es) Formas cristalinas de 5-cloro-N2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-N4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
WO2022028346A1 (zh) 一种芳香类化合物及其在抗肿瘤药物中的应用
TW201904966A (zh) Fgfr抑制劑之結晶形式及其製備方法
CN102295635B (zh) 抗肿瘤药物四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用
JP2021532077A (ja) セレブロン系機構に対抗する二量体免疫調節化合物
TW201105326A (en) Diamino heterocyclic carboxamide compound
CN101421247B (zh) 咪唑衍生物、其制备方法和其作为药物的用途
ES2908424T3 (es) Forma cristalina y tipo de sal del compuesto triazolopirimidina y método de preparación de la misma
CN116670119A (zh) 作为btk抑制剂的桥联双环化合物
CN103214467B (zh) 5-[[4-[(2,3-二甲基-2h-吲唑-6-基)甲氨基]-2嘧啶基]氨基]-2-甲基-苯磺酰胺衍生物及其制备方法与应用
EP4604963A2 (en) Covalent inhibitors of wild-type and mutant pi3k and method of uses thereof
CN106543194A (zh) 水仙环素衍生物及其制备与在制备抗肿瘤药物中的应用
WO2023183936A2 (en) Combination therapy of a pi3k inhibitor and kras inhibitor and methods of use thereof
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
HK1173433A (en) Hydroxamic acid derivatives
CN117624161A (zh) 一种吡啶羧酸胺衍生物及其应用
CN115368277B (zh) 一种含异羟肟酸结构的联苯类化合物及其应用
EP3334707B1 (en) A process for the preparation of the compound n-(3,5-dimethylphenyl)-n'-(2-trifluoromethylphenyl) guanidine
CN106905241B (zh) 1,2-二取代苯并咪唑衍生物及其应用
WO2024000615A1 (zh) 一种酪氨酸蛋白激酶抑制剂及其用途
HK1251879B (zh) 作为erk抑制剂的苯胺嘧啶衍生物
HK1256253B (en) A process for the preparation of the compound n-(3,5-dimethylphenyl)-n'-(2-trifluoromethylphenyl) guanidine
CN105001290A (zh) 双嘧啶碱基三环核苷类化合物、其制备方法及应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1173433

Country of ref document: HK

C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: 311100 No. 36, Linping Avenue, Yuhang economic and Technological Development Zone, Hangzhou, Zhejiang

Applicant after: Hangzhou Minsheng Pharmaceutical Co., Ltd.

Applicant after: Northlake Biosciences LLC

Address before: 310011 No. 108 Tong Road, Hangzhou, Zhejiang, Yuhang

Applicant before: Hangzhou Minsheng Pharmaceutical Co., Ltd.

Applicant before: Northlake Biosciences LLC

C14 Grant of patent or utility model
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: 311100 No. 36, Linping Avenue, Yuhang economic and Technological Development Zone, Zhejiang, Hangzhou

Applicant after: Hangzhou Minsheng Pharmaceutical Co., Ltd.

Applicant after: Northlake Biosciences LLC

Address before: 311100 No. 36, Linping Avenue, Yuhang economic and Technological Development Zone, Hangzhou, Zhejiang

Applicant before: Hangzhou Minsheng Pharmaceutical Co., Ltd.

Applicant before: Northlake Biosciences LLC

GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20170711

Address after: 311100 No. 36, Linping Avenue, Yuhang economic and Technological Development Zone, Zhejiang, Hangzhou

Patentee after: Hangzhou Minsheng Pharmaceutical Co., Ltd.

Address before: 311100 No. 36, Linping Avenue, Yuhang economic and Technological Development Zone, Zhejiang, Hangzhou

Co-patentee before: Northlake Biosciences LLC

Patentee before: Hangzhou Minsheng Pharmaceutical Co., Ltd.

TR01 Transfer of patent right

Effective date of registration: 20180531

Address after: 310052 201, room 1, 658 Binan Road, Changhe street, Binjiang District, Hangzhou, Zhejiang.

Patentee after: Hangzhou stno medical science and Technology Co., Ltd.

Address before: 311100 Linping Avenue, Yuhang economic and Technological Development Zone, Hangzhou, Zhejiang 36

Patentee before: Hangzhou Minsheng Pharmaceutical Co., Ltd.

TR01 Transfer of patent right